State Street Corp Has $19.03 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

State Street Corp raised its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 2.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,321,248 shares of the company's stock after purchasing an additional 57,822 shares during the period. State Street Corp owned 1.86% of Wave Life Sciences worth $19,034,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Wave Life Sciences by 23.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company's stock valued at $37,000 after acquiring an additional 856 shares during the last quarter. Mackenzie Financial Corp increased its holdings in shares of Wave Life Sciences by 13.6% in the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company's stock valued at $79,000 after buying an additional 1,905 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Wave Life Sciences by 3.4% during the 2nd quarter. Rhumbline Advisers now owns 125,834 shares of the company's stock valued at $628,000 after acquiring an additional 4,092 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Wave Life Sciences by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 139,790 shares of the company's stock worth $698,000 after acquiring an additional 4,914 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Wave Life Sciences by 53.9% in the 3rd quarter. US Bancorp DE now owns 18,043 shares of the company's stock worth $148,000 after acquiring an additional 6,316 shares during the last quarter. Institutional investors and hedge funds own 89.73% of the company's stock.

Insider Activity

In other Wave Life Sciences news, insider Chris Francis sold 36,000 shares of Wave Life Sciences stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $576,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kyle Moran sold 17,146 shares of the stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $9.00, for a total transaction of $154,314.00. Following the sale, the chief financial officer now directly owns 19,777 shares in the company, valued at approximately $177,993. This represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 453,690 shares of company stock worth $6,425,883. Corporate insiders own 29.10% of the company's stock.

Wave Life Sciences Trading Up 2.2 %

WVE stock traded up $0.29 during trading on Tuesday, reaching $13.41. 354,517 shares of the stock were exchanged, compared to its average volume of 1,114,860. The company has a market capitalization of $2.05 billion, a P/E ratio of -12.08 and a beta of -1.21. Wave Life Sciences Ltd. has a twelve month low of $3.50 and a twelve month high of $16.74. The stock has a 50 day simple moving average of $14.41 and a 200-day simple moving average of $9.07.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on WVE shares. StockNews.com lowered shares of Wave Life Sciences from a "hold" rating to a "sell" rating in a report on Wednesday, November 13th. B. Riley raised their target price on Wave Life Sciences from $19.00 to $22.00 and gave the stock a "buy" rating in a research report on Monday, November 4th. JPMorgan Chase & Co. upped their price target on Wave Life Sciences from $13.00 to $17.00 and gave the company an "overweight" rating in a research report on Thursday, October 17th. Royal Bank of Canada lifted their target price on Wave Life Sciences from $7.00 to $15.00 and gave the company a "sector perform" rating in a research note on Monday, October 21st. Finally, Leerink Partners increased their price target on shares of Wave Life Sciences from $20.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $22.22.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.